Specific inhibition of ERBB3 by either shRNA or a novel neutralizing antibody [24–26] in combination with fucoidan partly recapitulated these effects, reiterating the ERBB3 pathway is a major player in melanoma cell survival. Here, ERBB3 is linked to melanoma.